- Home
- IBO vs CARA Comparison
IBO vs CARA Comparison
Compare IBO & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- CARA
- Stock Information
- Founded
- IBO 2018
- CARA 2004
- Country
- IBO United States
- CARA United States
- Employees
- IBO N/A
- CARA N/A
- Industry
- IBO
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- CARA Health Care
- Exchange
- IBO NYSE
- CARA Nasdaq
- Market Cap
- IBO 16.5M
- CARA 16.7M
- IPO Year
- IBO 2024
- CARA 2014
- Fundamental
- Price
- IBO $1.57
- CARA $0.25
- Analyst Decision
- IBO
- CARA Hold
- Analyst Count
- IBO 0
- CARA 3
- Target Price
- IBO N/A
- CARA $1.00
- AVG Volume (30 Days)
- IBO 32.6K
- CARA 1.6M
- Earning Date
- IBO 11-12-2024
- CARA 11-14-2024
- Dividend Yield
- IBO N/A
- CARA N/A
- EPS Growth
- IBO N/A
- CARA N/A
- EPS
- IBO 0.01
- CARA N/A
- Revenue
- IBO N/A
- CARA $8,686,000.00
- Revenue This Year
- IBO N/A
- CARA N/A
- Revenue Next Year
- IBO N/A
- CARA N/A
- P/E Ratio
- IBO $187.06
- CARA N/A
- Revenue Growth
- IBO N/A
- CARA N/A
- 52 Week Low
- IBO $1.22
- CARA $0.23
- 52 Week High
- IBO $3.25
- CARA $1.15
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- CARA 41.07
- Support Level
- IBO N/A
- CARA $0.24
- Resistance Level
- IBO N/A
- CARA $0.30
- Average True Range (ATR)
- IBO 0.00
- CARA 0.02
- MACD
- IBO 0.00
- CARA -0.00
- Stochastic Oscillator
- IBO 0.00
- CARA 40.45
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.